Showing 581-590 of 10541 results for "".
The Value of Radiation as an Option for BCC and SCC
https://practicaldermatology.com/issues/may-june-2025/the-value-of-radiation-as-an-option-for-bcc-and-scc/35919/The Skin Cancer Foundation calls Mohs micrographic surgery the gold standard for treating basal cell carcinomas and squamous cell carcinomas.SCALE 2024: Listen as Dr. Joel Cohen and Dr. Suneel Chilukuri on Microwave Therapy
https://practicaldermatology.com/error/404/Suneel Chilukuri, MD, discusses the various applications of microwave therapy, including non-melanoma skin cancer, with Joel Cohen, MD, at Music City SCALE.Low-Nickel Diets Show Promise for Contact Dermatitis
https://practicaldermatology.com/conferences/maui-derm-2024/low-nickel-diets-show-promise-for-contact-dermatitis/20256/Matthew Zirwas, MD, discusses his experience with the “low-nickel diet” for patients who have systemic reactions to dietary nickel.What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thEyeing a Treatment for Syringoma
https://practicaldermatology.com/videos/scientifically-speaking/eyeing-a-treatment-for-syringoma/20112/Listen as Joel L. Cohen, MD describes early evidence for the use of nano pulse stimulation to treat syringoma, a notoriously challenging target.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneDermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraEnsuring Excellent Care Across LGBTQ and Sexual Minority Patients
https://practicaldermatology.com/topics/practice-management/ensuring-excellent-care-across-lgbtq-and-sexual-minority-patients/20077/The session on LGBTQ and sexual gender minority health covered a range of topics including both clinical care as well as terminology, structures, and framework. Klint Peebles, MD talks about the importance of providing excellent dermatologic care as patients face disparities and challenges in accessDermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P